A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

This Phase 3 clinical trial tests an experimental injectable medication called HRS-9531 to see if it reduces the severity of obstructive sleep apnea (OSA) in adults who are obese and already using a CPAP or similar breathing device. OSA causes repeated pauses in breathing during sleep, and excess weight is a major contributing factor; this drug targets weight-related mechanisms that may also affect airway function. Eligible participants are adults aged 18–75 with a BMI of 28 or higher, confirmed moderate-to-severe OSA, and at least 3 months of ongoing CPAP therapy, without diabetes or major upper airway abnormalities. Participation involves receiving injections of the study drug or a placebo over a treatment period, along with sleep studies and regular clinical visits. This summary was prepared to help patients understand the study in plain language.